Search PubMed⌕ Search

PubMed · 2829605

Tuberculin sensitivity in tuberculosis.

Abstract

Seven of twenty-eight (25%) patients with untreated tuberculosis had skin induration of less than 6 mm to one tuberculin unit (TU), and 3 (11%) to 10 TU PPD. Among twenty-four patients with lung disease, there were no detectable differences in radiological extent of disease between reactors and non-reactors to low-dose tuberculin. However, non-reactors were significantly more malnourished (P less than 0.02), excreted more bacilli (P less than 0.02) and took longer for sputum sterilization during chemotherapy (P less than 0.01). Early skin reactions (6-8 h) occurred in fourteen of twenty-four (58%) patients, but in none of twenty-four matched healthy controls (P less than 0.0001); the proportions giving delayed (48-72 h) reactions were similar. Although the patients had larger delayed reactions as a group (P = 0.04), this would not have been of value in making the diagnosis. Repeat tuberculin testing of subjects had a booster effect, but did not induce hypersensitivity in initially healthy non-reactors. All nutritional abnoalities observed in the patients, except arm muscle circumference and serum albumin, reverted to normal during chemotherapy, concomitant with clinical improvement and an increase in dermal reactivity to tuberculin. Antigen overload may lead to both skin anergy and undernutrition. The accelerated tuberculin skin reaction could offer a practical and specific, although not particularly sensitive, method of aiding the diagnosis of active tuberculosis.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J K Onwubalili. 1987. Tuberculin sensitivity in tuberculosis.. https://pubmed.ncbi.nlm.nih.gov/2829605/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Mechanism of thioamide drug action against tuberculosis and leprosy.

Thioamide drugs, ethionamide (ETH) and prothionamide (PTH), are clinically effective in the treatment of Mycobacterium tuberculosis, M. leprae, and M. avium complex infections. Although generally considered second-line drugs for tuberculosis, their use has increased considerably as the number of multidrug resistant and extensively drug resistant tuberculosis cases continues to rise. Despite the widespread use of thioamide drugs to treat tuberculosis and leprosy, their precise mechanisms of action remain unknown. Using a cell-based activation method, we now have definitive evidence that both thioamides form covalent adducts with nicotinamide adenine dinucleotide (NAD) and that these adducts are tight-binding inhibitors of M. tuberculosis and M. leprae InhA. The crystal structures of the inhibited M. leprae and M. tuberculosis InhA complexes provide the molecular details of target-drug interactions. The purified ETH-NAD and PTH-NAD adducts both showed nanomolar Kis against M. tuberculosis and M. leprae InhA. Knowledge of the precise structures and mechanisms of action of these drugs provides insights into designing new drugs that can overcome drug resistance.

Antitubercular Agents↗

EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.

Many of the current antimycobacterial agents require some form of cellular activation unmasking reactive groups, which in turn will bind to their specific targets. Therefore, understanding the mechanisms of activation of current antimycobacterials not only helps to decipher mechanisms of drug resistance but may also facilitate the development of alternative activation strategies or of analogues that do not require such processes. Herein, through the use of genetically defined strains of Mycobacterium bovis BCG we provide evidence that EthA, previously shown to activate ethionamide, also converts isoxyl (ISO) and thiacetazone (TAC) into reactive species. These results were further supported by the development of an in vitro assay using purified recombinant EthA, which allowed direct assessment of the metabolism of ISO. Interestingly, biochemical analysis of [(14)C]acetate-labeled cultures suggested that all of these EthA-activated drugs inhibit mycolic acid biosynthesis via different mechanisms through binding to specific targets. This report is also the first description of the molecular mechanism of action of TAC, a thiosemicarbazone antimicrobial agent that is still used in the treatment of tuberculosis as a second-line drug in many developing countries. Altogether, the results suggest that EthA is a common activator of thiocarbamide-containing drugs. The broad specificity of EthA can now be used to improve the activation process of these drugs, which may help overcome the toxicity problems associated with clinical thiocarbamide use.

Antitubercular Agents↗